Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.57 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.57 |
| ▸ | HTR3B | O95264 | 1/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 1/20 | 0.57 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.57 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.52 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.52 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1969103 | 0.98 | LMNA (0.58) | CYP2C19HTR3EHTR3BADRB1DRD2 | |
| Hydrochloric Acid SCHEMBL30069211 | 0.98 | LMNA (0.58) | CYP2C19HTR3EHTR3BADRB1DRD2 | |
| Hydrochloric Acid SCHEMBL26600676 | 0.98 | LMNA (0.58) | CYP2C19HTR3EHTR3BADRB1DRD2 | |
| Hydrochloric Acid SCHEMBL30069213 | 0.98 | LMNA (0.58) | CYP2C19HTR3EHTR3BADRB1DRD2 | |
| SCHEMBL12986602 | 0.94 | HTR3A (0.51) | CYP2C19HTR3EHTR3BADRB1DRD2 | |
| Hydrochloric Acid SCHEMBL1063578 | 0.93 | LMNA (0.52) | CYP2C19HTR3EHTR3BADRB1DRD2 | |
| SCHEMBL30585959 | 0.85 | SLC2A1 (0.52) | CYP2C19DRD2DRD3MAPTSLC2A1 | |
| SCHEMBL29086088 | 0.85 | SLC2A1 (0.52) | CYP2C19DRD2DRD3MAPTSLC2A1 | |
| SCHEMBL15533598 | 0.84 | EPHX2 (0.52) | EPHX2HTR1ASLC6A2ALDH1A1 | |
| SCHEMBL31652008 | 0.84 | EPHX2 (0.49) | CYP2C19HTR3EHTR3BADRB1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| CN-112154145-B | Piperazine azaspiro derivatives | 辉瑞大药厂 | 2023-10-17 | — | — | CN | disclosed |
| EP-4219464-A1 | PIPERAZINE AZASPIRO DERIVAVES | Pfizer Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219464-A1 | PIPERAZINE AZASPIRO DERIVAVES | Pfizer Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | PFIZER INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | PFIZER INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | PFIZER INC. | 2023-06-22 | — | — | US | disclosed |
| EP-3768669-B1 | PIPERAZINE AZASPIRO DERIVAVES | PFIZER (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-0645385-A1 | Antimigraine cyclobutenedione derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines | Bristol-Myers Squibb Company (US) | 1995-03-29 | — | — | EP | disclosed |
| EP-0345808-B1 | 1-Indolylalkyl-4-(substituted-pyridinyl)piperazines | BRISTOL MYERS SQUIBB CO (US) | 1995-01-11 | — | — | EP | disclosed |
| US-4954502-A | Antidepressants | BRISTOL-MYERS SQUIBB COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0200968-B1 | SUCCINIMIDE DERIVATIVES, THEIR PRODUCTION AND USE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-08-29 | — | — | EP | disclosed |
| EP-0345808-A1 | 1-Indolylalkyl-4-(substituted-pyridinyl)piperazines | Bristol-Myers Squibb Company (US) | 1989-12-13 | — | — | EP | disclosed |
| US-4843078-A | ANXIOLYTIC AGENTS | SUMITONO PHARMACEUTICAL COMPANY, LIMITED (JP) | 1989-06-27 | — | — | US | disclosed |
| US-4757073-A | Antipsychotic agents | BRISTOL-MYERS COMPANY (US) | 1988-07-12 | — | — | US | disclosed |
| EP-0200968-A1 | Succinimide derivatives, their production and use | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1986-11-12 | — | — | EP | disclosed |
| US-4619930-A | Antipsychotic cyclic imide derivatives of 2-(4-butylpiperazin-1-yl)pyridines, compositions and use | BRISTOL-MYERS COMPANY (US) | 1986-10-28 | — | — | US | disclosed |
| US-4305944-A | TRANQUILIZERS, NEUROLEPTIC AGENTS | MEAD JOHNSON & COMPANY (US) | 1981-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192654-A1 | PIPERAZINE AZASPIRO DERIVATIVES | CHRM1, CHRM2, CHRM5 | CYP2C19 502/4885HTR3E 1289/4885HTR3B 479/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | CYP2C19 2761/4885HTR3E 4256/4885HTR3B 3634/4885 |
| US-20250214977-A1 | STAT6 INHIBITORS AND USES THEREOF | STAT6, STAT5B, STAT5A | CYP2C19 4391/4885HTR3E 2136/4885HTR3B 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.